Johnson & Johnson shares test modest upside with bullish MACD flashing 'Strong Buy': weekly analysis

Traders Union
All News
Stocks
Johnson & Johnson gains 1.03% this week

Highlights

Shares of Johnson & Johnson gained $2.6 in the past week and remain in a long-term bullish structure.
The stock is consolidating within a narrow range, with buyers showing a modest advantage but momentum signals remain mixed.
Short-term trading is expected between $263.81 and $279.27, with 75% probability for an upside move if resistance is surpassed.

Portfolio shifts and trial miss drive sentiment amid corporate newsflow

On September 14, 2026, Johnson & Johnson reported that its experimental treatment JNJ-5120/PIPE-307 did not achieve the primary endpoint in a key phase 2 trial for major depressive disorder, according to GuruFocus. Bloomberg, as reported by Yahoo Finance, noted JNJ is in advanced talks to sell its DePuy Synthes orthopedics business to Apollo Global Management in a transaction potentially worth close to $20 billion, a move that could advance JNJ's portfolio transformation and refocus resources on core therapeutic areas. Also on September 14, 2026, JNJ published its 2026 Oncology Care Index, highlighting increased AI adoption in community oncology although advanced predictive models remain underused.

Bullish MACD signal weighs against neutral RSI as range holds this week

The daily chart shows the stock contained within a narrow range, with momentum described as a contained move within a narrow range and 7-day volatility at 3.79%. Despite a bullish MACD signal (1.1, "Strong Buy"), momentum indicators present a mixed picture with the RSI remaining in neutral territory at 51.02 and Stochastic RSI registering as oversold at 14.71. Immediate support is in play at $267.06 (Ichimoku Kijun), with the next resistance level seen at the MA-20 of $269.85. This mix suggests buyers hold a modest advantage but momentum is not yet clearly directional.

Breakout risk builds if support or resistance levels give way next week

In the week ahead, Johnson & Johnson is expected to trade between $263.81 and $279.27. There is a 75% probability of an increase and a 25% probability of a decrease, based on the current signals. The base case is for consolidation between the support at $267.06 and resistance at $269.85. A clear breakout above $269.85 opens the way for further upside toward the top of the weekly range, while a sustained move below $267.06 would expose the stock to a deeper pullback within the expected range.

Sholanke Dele, market strategist, sees the cautious tone around Johnson & Johnson stock persisting as technical uncertainty and unimpressive news flow weigh on sentiment. The failed outcome for the JNJ-5120/PIPE-307 trial does little to dispel doubts, even as deal talks surrounding the DePuy Synthes unit gesture at strategic realignment. Technically, a modestly bullish MACD is offset by neutral RSI and an oversold Stochastic RSI, with shares locked between support at $267.06 and resistance at $269.85. Dele believes consolidation is the base case, and conviction will only improve on a decisive break outside this range. "Without a clear bullish catalyst or price strength above $269.85, my bias stays defensive for the week ahead."

Previously it was reported that Johnson & Johnson was exploring a sale of its DePuy Synthes orthopedics business as part of a broader portfolio realignment. With mixed momentum signals and several new developments, the key level to watch is a decisive move beyond the $269.85 resistance, which could set the stage for upside toward the top of the weekly forecasted range.

Source of Data: JNJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.